7,019 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by Meiji Yasuda Asset Management Co Ltd.

Meiji Yasuda Asset Management Co Ltd. acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 7,019 shares of the biotechnology company’s stock, valued at approximately $234,000.

Other institutional investors have also recently made changes to their positions in the company. Principal Securities Inc. raised its holdings in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 373 shares during the last quarter. USA Financial Formulas purchased a new position in shares of Exelixis in the fourth quarter valued at about $32,000. Kestra Investment Management LLC bought a new position in shares of Exelixis during the fourth quarter valued at about $39,000. UMB Bank n.a. boosted its holdings in shares of Exelixis by 68.4% during the fourth quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 553 shares during the period. Finally, Crowley Wealth Management Inc. bought a new stake in shares of Exelixis in the fourth quarter worth about $50,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Stock Down 0.4 %

Shares of EXEL opened at $36.70 on Friday. The company has a market capitalization of $10.27 billion, a P/E ratio of 20.73, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $40.02. The firm has a 50 day moving average of $35.71 and a 200 day moving average of $33.22.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, sell-side analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analyst Weigh In

EXEL has been the subject of a number of recent analyst reports. Oppenheimer lowered Exelixis from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $41.00 to $33.00 in a research report on Friday, January 24th. Truist Financial raised their price target on Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Stifel Nicolaus upped their price objective on shares of Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a report on Wednesday, February 12th. Citigroup lifted their target price on shares of Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Finally, JMP Securities reissued a “market outperform” rating and issued a $41.00 price target on shares of Exelixis in a research note on Thursday, January 23rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $37.59.

Insider Buying and Selling

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $36.98, for a total value of $1,946,479.28. Following the transaction, the executive vice president now directly owns 303,310 shares of the company’s stock, valued at approximately $11,216,403.80. This trade represents a 14.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Mary C. Beckerle sold 12,210 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the sale, the director now directly owns 30,406 shares of the company’s stock, valued at $1,060,561.28. The trade was a 28.65 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is owned by insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.